These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33188827)

  • 1. Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors.
    Lorkowski ME; Atukorale PU; Bielecki PA; Tong KH; Covarrubias G; Zhang Y; Loutrianakis G; Moon TJ; Santulli AR; Becicka WM; Karathanasis E
    J Control Release; 2021 Feb; 330():1095-1105. PubMed ID: 33188827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors.
    Bielecki PA; Lorkowski ME; Becicka WM; Atukorale PU; Moon TJ; Zhang Y; Wiese M; Covarrubias G; Ravichandran S; Karathanasis E
    Nanoscale Horiz; 2021 Feb; 6(2):156-167. PubMed ID: 33400743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer.
    Chibaya L; DeMarco KD; Lusi CF; Kane GI; Brassil ML; Parikh CN; Murphy KC; Chowdhury SR; Li J; Ma B; Naylor TE; Cerrutti J; Mori H; Diaz-Infante M; Peura J; Pitarresi JR; Zhu LJ; Fitzgerald KA; Atukorale PU; Ruscetti M
    Sci Transl Med; 2024 Aug; 16(762):eadj9366. PubMed ID: 39196958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.
    Atukorale PU; Raghunathan SP; Raguveer V; Moon TJ; Zheng C; Bielecki PA; Wiese ML; Goldberg AL; Covarrubias G; Hoimes CJ; Karathanasis E
    Cancer Res; 2019 Oct; 79(20):5394-5406. PubMed ID: 31431457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers.
    Atukorale PU; Moon TJ; Bokatch AR; Lusi CF; Routhier JT; Deng VJ; Karathanasis E
    Nanoscale; 2022 Jan; 14(4):1144-1159. PubMed ID: 35023530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the uptake of untargeted and targeted immunostimulatory nanoparticles by immune cells in the microenvironment of metastatic breast cancer.
    Covarrubias G; Moon TJ; Loutrianakis G; Sims HM; Umapathy MP; Lorkowski ME; Bielecki PA; Wiese ML; Atukorale PU; Karathanasis E
    J Mater Chem B; 2022 Jan; 10(2):224-235. PubMed ID: 34846443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of PEGylation on the efficacy and uptake of an immunostimulatory nanoparticle in the tumor immune microenvironment.
    Becicka WM; Bielecki PA; Lorkowski ME; Moon TJ; Zhang Y; Atukorale PU; Covarrubias G; Karathanasis E
    Nanoscale Adv; 2021 Aug; 3(17):4961-4972. PubMed ID: 34485818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration.
    Li K; Wang J; Zhang R; Zhou J; Espinoza B; Niu N; Wang J; Jurcak N; Rozich N; Osipov A; Henderson M; Funes V; Lyman M; Blair AB; Herbst B; He M; Yuan J; Trafton D; Yuan C; Wichroski M; Liu X; Fu J; Zheng L
    J Hematol Oncol; 2024 Aug; 17(1):62. PubMed ID: 39113096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle delivery of innate immune agonists combines with senescence-inducing agents to mediate T cell control of pancreatic cancer.
    Chibaya L; Lusi CF; DeMarco KD; Kane GI; Brassil ML; Parikh CN; Murphy KC; Li J; Naylor TE; Cerrutti J; Peura J; Pitarresi JR; Zhu LJ; Fitzgerald KA; Atukorale PU; Ruscetti M
    bioRxiv; 2023 Sep; ():. PubMed ID: 37790484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Photoactivatable Self-Assembled Nanoagonist for Synergistic Therapy against Pancreatic Ductal Adenocarcinoma.
    Xu X; Li T; Yang T; Liu F; Guo Z; Wu H; Tang Y; Chen H
    Nano Lett; 2024 Oct; 24(39):12239-12248. PubMed ID: 39248330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model.
    Capacio BA; Shankara Narayanan JS; Vicente DA; Liu Y; LaPorte JP; Cox BF; Jaroch DB; Katz SC; White RR
    Surgery; 2023 Sep; 174(3):666-673. PubMed ID: 37391328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
    Lu ZD; Chen YF; Shen S; Xu CF; Wang J
    ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy.
    Luo L; Wang X; Liao YP; Chang CH; Nel AE
    ACS Nano; 2022 Aug; 16(8):13168-13182. PubMed ID: 35920660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.
    Lebedeva E; Bagaev A; Pichugin A; Chulkina M; Lysenko A; Tutykhina I; Shmarov M; Logunov D; Naroditsky B; Ataullakhanov R
    BMC Immunol; 2018 Jul; 19(1):26. PubMed ID: 30055563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal co-delivery of toll-like receptors 3 and 7 agonists induce a hot triple-negative breast cancer immune environment.
    Nguyen BL; Phung CD; Pham DV; Le ND; Jeong JH; Kim J; Kim JH; Chang JH; Jin SG; Choi HG; Ku SK; Kim JO
    J Control Release; 2023 Sep; 361():443-454. PubMed ID: 37558053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment-Responsive Nanoparticles Amplifying STING Signaling Pathway for Cancer Immunotherapy.
    Liu D; Liang S; Ma K; Meng QF; Li X; Wei J; Zhou M; Yun K; Pan Y; Rao L; Chen X; Wang Z
    Adv Mater; 2024 Feb; 36(6):e2304845. PubMed ID: 37723642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity.
    Chamma H; Vila IK; Taffoni C; Turtoi A; Laguette N
    Cancer Lett; 2022 Jul; 538():215694. PubMed ID: 35489447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
    Jing W; McAllister D; Vonderhaar EP; Palen K; Riese MJ; Gershan J; Johnson BD; Dwinell MB
    J Immunother Cancer; 2019 Apr; 7(1):115. PubMed ID: 31036082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.